search for




 

Oral Spironolactone Treatment in Chronic Central Serous Chorioretinopathy
만성 중심장액맥락망막병증에서 경구 스피로놀락톤의 효과
JKOS 2020 Mar;61(3):250-7
Published online March 15, 2020;  https://doi.org/10.3341/jkos.2020.61.3.250
Copyright © 2020 The Korean Ophthalmological Society.
PDF Download Count: 66 / View Count: 57

Sae Rom Chung, MD1, Jin Gu Jeong, MD1, Tae Eun Lee, MD1,2,3, In Cheon You, MD, PhD1,2,3, Min Ahn, MD, PhD1,2,3, Nam Chun Cho, MD, PhD1,2,3
정새롬1⋅정진구1⋅이태은1,2,3⋅유인천1,2,3⋅안 민1,2,3⋅조남천1,2,3

Department of Ophthalmology, Jeonbuk National University Medical School1, Jeonju, Korea
Research Institute of Clinical Medicine of Jeonbuk National University2, Jeonju, Korea
Biomedical Research Institute, Jeonbuk National University Hospital3, Jeonju, Korea
전북대학교 의학전문대학원 안과학교실1, 전북대학교 임상의학연구소2, 전북대학교병원 의생명연구원3
Received May 22, 2019; Revised September 11, 2019; Accepted February 21, 2020.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
 Abstract
Purpose: To evaluate the effect of oral spironolactone for non-resolving chronic central serous chorioretinopathy after intravitreal bevacizumab injection.
Methods: Seventeen eyes of 17 patients with non-resolving chronic central serous chorioretinopathy after intravitreal bevacizumab injection from September 2017 to December 2018 were treated with oral spironolactone for 6 months, and changes in central macular thickness, subretinal fluid height, and best-corrected visual acuity (BCVA) were analyzed retrospectively.
Results: The central macular thickness decreased from 309.94 ± 105.20 µm at baseline to 259.76 ± 81.83 µm at 3 months, and 243.11 ± 61.98 µm at 6 months, which were both statistically significant (Wilcoxon signed-rank test, p = 0.016 and p = 0.001, respectively). The subretinal fluid height decreased from 138.05 ± 95.69 µm at baseline to 70.88 ± 83.13 µm at 3 months, and 54.00 ± 56.25 µm at 6 months, which were both statistically significant (Wilcoxon signed-rank test, p = 0.002 and p = 0.000, respectively). The BCVA (LogMAR) changed from 0.30 ± 0.38 at baseline to 0.35 ± 0.43 at 1 month, 0.29 ± 0.43 at 3 months, and 0.26 ± 0.40 at 6 months. The results at 6 months were statistically significant (Wilcoxon signed-rank test, p = 0.033). There were no side effects in patients treated with oral spironolactone.
Conclusions: In chronic central serous chorioretinopathy, treatment with oral spironolactone significantly reduced the central macular thickness, subretinal fluid height, and the BCVA, without side effects.
Keywords : Bevacizumab, Central serous chorioretinopathy, Spironolactone

 

March 2020, 61 (3)